Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BofA/Merrill Lynch Upgrades Pacira Pharmaceuticals (PCRX) to Neutral (Earlier)
July 31, 2015 9:48 AM EDTBofA/Merrill Lynch earlier upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Underperform to Neutral with a price target of $69.00 (from $70.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $61.80 yesterday.
... MorePacira Pharma (PCRX) Misses Q2 EPS by 1c
July 30, 2015 8:17 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.23, $0.01 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $62.97 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More